Euroapi S.A.

ENXTPA:EAPI Stock Report

Market Cap: €335.5m

Euroapi Valuation

Is EAPI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EAPI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: EAPI (€3.52) is trading below our estimate of fair value (€18.77)

Significantly Below Fair Value: EAPI is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EAPI?

Key metric: As EAPI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for EAPI. This is calculated by dividing EAPI's market cap by their current revenue.
What is EAPI's PS Ratio?
PS Ratio0.3x
Sales€971.30m
Market Cap€335.52m

Price to Sales Ratio vs Peers

How does EAPI's PS Ratio compare to its peers?

The above table shows the PS ratio for EAPI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average23.3x
BOI Boiron
1x3.6%€487.9m
MEDCL MedinCell
42.4x50.6%€506.7m
VETO Vetoquinol
1.7x3.8%€938.3m
AB AB Science
48.2xn/a€52.1m
EAPI Euroapi
0.3x-0.2%€335.5m

Price-To-Sales vs Peers: EAPI is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (23.3x).

Price to Sales Ratio vs Industry

How does EAPI's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

23 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.9x5.3%
EAPI Euroapi
 0.3x-0.2%US$349.39m
EAPI 0.3xIndustry Avg. 2.9xNo. of Companies35PS0612182430+
23 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.9x17.1%
EAPI Euroapi
 0.3x73.1%US$349.39m
No more companies

Price-To-Sales vs Industry: EAPI is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is EAPI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EAPI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ratio1.1x

Price-To-Sales vs Fair Ratio: EAPI is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EAPI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€3.52
€3.28
-6.9%
17.1%€4.40€3.00n/a5
Nov ’25€3.87
€3.28
-15.2%
17.1%€4.40€3.00n/a5
Oct ’25€3.76
€3.24
-13.8%
18.1%€4.40€2.80n/a5
Sep ’25€4.16
€3.24
-22.1%
18.1%€4.40€2.80n/a5
Aug ’25€3.93
€3.30
-16.1%
29.3%€5.20€2.50n/a5
Jul ’25€2.63
€3.40
+29.4%
28.1%€5.20€2.50n/a5
Jun ’25€3.61
€3.52
-2.5%
24.6%€5.20€2.90n/a5
May ’25€2.95
€4.72
+59.9%
48.6%€9.00€2.90n/a5
Apr ’25€2.80
€4.72
+68.9%
48.6%€9.00€2.90n/a5
Mar ’25€4.00
€7.20
+80.0%
30.6%€10.50€4.50n/a5
Feb ’25€5.99
€8.36
+39.5%
32.7%€11.80€4.50n/a5
Jan ’25€5.73
€8.55
+49.2%
32.9%€11.80€4.50n/a6
Dec ’24€5.30
€9.91
+87.1%
33.5%€16.00€5.00n/a7
Nov ’24€5.10
€10.66
+109.1%
36.6%€16.00€5.00€3.877
Oct ’24€11.93
€15.10
+26.6%
7.9%€16.90€13.00€3.767
Sep ’24€12.64
€15.10
+19.5%
7.9%€16.90€13.00€4.167
Aug ’24€12.42
€14.60
+17.6%
9.1%€16.90€13.00€3.937
Jul ’24€10.50
€14.87
+41.7%
8.4%€16.90€13.50€2.636
Jun ’24€9.90
€14.87
+50.2%
8.4%€16.90€13.50€3.616
May ’24€10.90
€14.87
+36.5%
8.4%€16.90€13.50€2.956
Apr ’24€10.53
€14.86
+41.2%
11.2%€18.00€13.50€2.805
Mar ’24€15.45
€18.70
+21.0%
7.1%€21.00€17.00€4.005
Feb ’24€14.98
€18.70
+24.8%
7.1%€21.00€17.00€5.995
Jan ’24€13.85
€18.50
+33.6%
5.4%€20.00€17.00€5.735
Dec ’23€17.11
€20.00
+16.9%
6.3%€22.00€18.00€5.305
Nov ’23€18.14
€19.67
+8.4%
7.0%€22.00€18.00€5.106

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Sanofi

€116.8b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€93.17

7D

2.0%

1Y

7.9%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.50

7D

0%

1Y

-57.2%

Eurofins Scientific

€8.9b

Provides various analytical testing and laboratory services worldwide.

ERF

€46.96

7D

3.3%

1Y

-12.0%